Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects

Clinical Therapeutics

Volumn 36, Issue 9, 2014, Pages 1217-1225

  Teng, Renli ^a   Kujacic, Mirjana ^b   Hsia, Judith ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

CYP2D6; Drug drug interaction; Pharmacokinetics; Ticagrelor; Venlafaxine

Indexed keywords

AR C 124910XX; CYTOCHROME P450 2D6; DESVENLAFAXINE; DRUG METABOLITE; TICAGRELOR; UNCLASSIFIED DRUG; VENLAFAXINE; ADENOSINE; AR C124910XX; PURINERGIC P2Y RECEPTOR ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CROSSOVER PROCEDURE; DECREASED APPETITE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION STUDY; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; SINGLE DRUG DOSE; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; DRUG INTERACTION; METABOLISM; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADENOSINE; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DESVENLAFAXINE SUCCINATE; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; VENLAFAXINE HYDROCHLORIDE; YOUNG ADULT;

EID: 84908611470     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.06.024     Document Type: Article

References (32)

1. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovas Ther. 2009;27:259-274.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
3. Brilinta prescribing information. http://www1.astrazeneca-us.com/pi/brilinta.pdf#page=1. Accessed May 21, 2014.
4. Butler K, Teng R. Pharmacokinetics pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70:65-77.
5. Teng R, Butler K. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects. Can J Clin Pharmacol. 2010;15:e426.
6. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487-496.
7. Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514-1521.
8. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047.
9. Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos. 2011;39:703-710.
10. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
11. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645-681.
12. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:477-487.
13. Teng R, Butler K. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers. Clin Ther. 2013;35:1025-1037.
14. Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Asses. 2013;2:30-39.
15. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012;27:55-67.
16. Lesperance F, Frasure-Smith N, Juneau M, et al. Depression and 1-year prognosis in unstable angina. Arch Intern Med. 2000;160:1354-1360.
17. Grace SL, Abbey SE, Kapral MK, et al. Effect of depression on five-year mortality after an acute coronary syndrome. Am J Cardiol. 2005;96:1179-1185.
18. Jedlitschky G, Greinacher A, Kroemer HK. Transporters in human platelets: physiologic function and impact for pharmacotherapy. Blood. 2012;119:3394-3402.
19. Tseng YL, Chiang ML, Lane HY, et al. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. Thromb Res. 2013;131:325-332.
20. Castro VM, Gallagher PJ, Clements CC, et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open. 2012;2:e000544.
21. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104:1475-1482.
22. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41:149-156.
23. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20:480-490.
24. Venlafaxine prescribing information. http://www.drugs.com/pro/venlafaxine.html. Accessed May 16, 2014.
25. Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26:39-67.
26. Troy SM, Parker VD, Fruncillo RJ, et al. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol. 1995;35:404-409.
27. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther. 2014;52:478-491.
28. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2299-2306.
29. Columbia University Medical Center (CUMC). Columbia-Suicide Severity Rating Scale (C-SSRS). http://www.cssrs.columbia.edu/index.html. Accessed March 20, 2014.
30. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48:689-723.
31. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874-877.
32. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16(3 Suppl. 2):54S-59S.